Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study.

Int J Womens Dermatol · 2025 · PMC12448166 · PMID 40978669

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significanceP = .063so close (0.05 < p ≤ 0.1)

The spironolactone group also showed a greater increase in hair density and diameter after treatment; however, the P -value only approached the cutoff but did not reach statistical significance ( P = .063).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.